Annual Report 2018 Active Biotech AB (publ)


Active Biotech’s Annual Report 2018 is now available for download at

The Annual Report will only be digitally distributed. The English version will be available within short.

Download as PDF

Lund, April 26, 2019
Active Biotech AB (publ)

Helén Tuvesson

For further information, please contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA (naptumumab), an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publicationat 11.00a.m CET on April 26, 2019.

Annual Report 2018 Active Biotech AB (publ)

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire